Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00338650
Status:
COMPLETED
Last Update Posted:
2007-11-29
First Post:
2006-06-19
Brief Title:
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohns Disease With Previous Exposure to Infliximab CHOICE
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
A Multi-Center Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients With Moderate to Severe Crohns Disease With Previous Exposure to Infliximab
Status:
COMPLETED
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohns Disease who have failed to respond to lost response to or are intolerant to infliximab and to evaluate safety
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CHOICE | None | None | None |